Dr Lal PathLabs Q1 FY27: key dates, Q4 FY26 numbers

What’s coming up on July 24

Dr. Lal PathLabs Ltd has scheduled a Board of Directors meeting on July 24, 2026 to consider and approve the unaudited financial results for the first quarter of FY26-27 (Q1 FY27). The date is also tagged as the upcoming earnings date for the company’s Q1 FY26-27 results. For investors, the meeting matters because it will provide the first official financial read for FY27, including trends in volumes, pricing, and costs. The company’s most recent disclosed quarter showed a mixed picture, with strong top-line growth but pressure on profitability on a year-on-year basis. That combination keeps attention on margins and operating discipline in the upcoming quarter.

Conference call scheduled after results

Alongside the results process, Dr. Lal PathLabs will host a conference call on July 24, 2026 to discuss its financial and operating performance for Q1 FY27. The call is scheduled for 5:30 PM IST. The company said the call will allow investors and analysts to engage with the leadership following the quarterly results announcement. Such calls typically focus on the quarter’s drivers, including volume growth, test mix, cost line items, and network expansion, but only the timing and purpose are explicitly stated here. For market participants, the combination of a board meeting and a call on the same day often concentrates attention on both headline numbers and management commentary.

Latest reported quarter: Q4 FY25-26 (ended March 2026)

The last earnings date is listed as Q4 FY25-26 on April 30, 2026. For that quarter, the dataset shows revenue of ₹702 crore, up 6.50% quarter-on-quarter (QoQ) and up 16.61% year-on-year (YoY). Gross profit is shown at ₹142 crore, up 3.64% QoQ and up 7.24% YoY. Net profit is listed at ₹132 crore, up 44.64% QoQ but down 14.98% YoY.

A separate set of quarterly figures also shows “Total Revenue” at ₹702.70 crore for Mar 2026. In the same table set, “Net Income” for Mar 26 is shown as ₹131.30 crore. These figures align broadly with the quarter’s revenue and profit scale presented elsewhere in the supplied text, but they are presented as separate line items.

Profit and cost lines shown for recent quarters

A quarterly comparison table (figures in ₹ crore, except per share values) lists “Total Revenue” at ₹669.80 crore for Jun 25 and ₹702.70 crore for Mar 26. In the same table, “Operating Income” is ₹157.70 crore (Jun 25) and ₹142.20 crore (Mar 26). “Total Operating Expense” is ₹512.10 crore (Jun 25) and ₹560.50 crore (Mar 26). “Depreciation/ Amortization” is ₹34.60 crore (Jun 25) and ₹44.60 crore (Mar 26).

The table also lists “Net Income” at ₹132.40 crore for Jun 25 and ₹131.30 crore for Mar 26, and “Diluted Normalized EPS” at 7.98 (Jun 25) and 7.85 (Mar 26). The dataset notes that the reported EPS for the company is 30.11, while the estimated EPS is shown as “--”. It also shows TTM EPS at 30.11 with a -1.68% YoY change.

Dividend and corporate actions in focus

On corporate actions, the text states that Dr Lal PathLabs Ltd has declared a dividend of ₹4.00 on 25 Jun, 2026. Another dividend detail in the supplied content notes a dividend of ₹4.00 declared on 30/04/2026 and describes it as declared one time in the current financial year (FY2026-2027). The content also mentions that the last bonus declared by the company was on 31 Oct, 2025.

There is also a separate news snippet stating the company’s board declared an interim dividend of ₹6 per share for the current fiscal in the context of a quarter where net profit declined 57% to ₹58 crore and revenue from operations declined to ₹503 crore (from ₹607 crore a year ago). Since the provided excerpt does not specify the year for this result event, it is best read as an additional reference point present in the supplied text rather than a confirmed FY27 action.

Block trade disclosure noted in recent updates

The update list includes a block trade item: “Dr. Lal Path Labs Records ₹20.56 Crore Block Trade on NSE at ₹1622.90 Per Share” dated Jun 29, 2026. The supplied text also includes a prompt-style question about how a block trade might affect liquidity and volatility, but it does not provide a definitive answer or quantified impact. What is explicit is the transaction size and price, which can draw attention because such trades may temporarily change near-term traded volumes.

Market snapshot and valuation indicators mentioned

A market snapshot in the supplied text (timestamped “as on June 17, 2026 at 4:01 pm IST”) lists a market cap of ₹27,526.12 crore. The same snapshot includes ROE of 25.27, ROCE of 29.72, P/B ratio of 9.71, beta (LTM) of 0.47, dividend yield of 0.97, EPS (TTM) of 29.445, book value of 129.96, and quarterly earnings growth YoY of -14.98.

Separately, the content also references dividend yield values of 1.24 and 1.27 in different contexts, and mentions a share price of ₹1,614.90 as on 26 May, 2026. Because these are shown as standalone snippets without a single consistent timestamp, they should be treated as point-in-time datapoints as presented in the source text.

Key facts table

Company contact details listed

The supplied text includes corporate contact information for Dr Lal PathLabs in Rohini, New Delhi (Delhi) with PIN code 110085. It lists a telephone number (011-49885050), a fax number (011-27882134), and an email (cs@lalpathlabs.com). While these details do not affect quarterly performance, they are part of the disclosed company information included in the dataset.

Why the July 24 update matters for investors

The July 24 board meeting and the post-results call are the key scheduled events explicitly disclosed in the text. They arrive after a quarter where revenue growth was strong, but net profit was down on a YoY basis even as it improved QoQ. The supplied analyst-style note in the text also flags that margins were weak in Q4FY26, citing network expansion and promotional costs as factors behind an EBITDA margin of 26.6% (down 150 bps). It also states management anticipates momentum in Delhi NCR and better traction in Suburban Diagnostics, with a stated FY27 revenue growth target of 13-15% and EBITDA margins between 27-28%.

Conclusion

Dr Lal PathLabs’ next major trigger is the July 24, 2026 board meeting to consider Q1 FY27 unaudited results, followed by a 5:30 PM IST conference call the same day. Recent disclosures show Q4 revenue of ₹702 crore with 16.61% YoY growth, while net profit of ₹132 crore was down 14.98% YoY. Investors will be watching the July 24 release and management interaction for updated commentary on volumes, margins, and cost trends, based on the results that will be approved at the meeting.